ResearchMoz

Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth

GBI Research
Published Date » 2013-05-14
No. Of Pages » N/A
   
 The leading business intelligence provider GBI Research has released its latest research report, entitled “Travel Vaccines Market to 2019 – Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth”. The report provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market.  
   
 The report analyzes the market for Travel Vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. In addition, it...
Table of Contents  

1 Table of Contents  
1.1 List of Tables  
1.2 List of Figures  
 
2 Travel Vaccines Market to 2019: Introduction  
2.1 Overview  
 
3 Travel Vaccines Market to 2019: Overview  
3.1 Vaccine-Preventable Diseases  
3.1.1 Types of Vaccines  
3.2 Regulatory Framework  
3.2.1 US  
3.2.2 UK  
3.2.3 France  
3.2.4 Germany  
3.2.5 Italy  
3.2.6 Spain  
3.2.7 Japan  
3.3 Vaccine Manufacturing Process  
 
4 Travel Vaccines Market to 2019: Market Characterization and Forecast  
4.1 Revenue Forecast  
4.2 Market Share by Vaccine Type  
4.3 Market Share by Geography  
4.4 Traveling Population  
4.5 Drivers  
4.5.1 Aging Population and Increase in Global Tourist Traffic  
4.5.2 Novel Vaccine Technologies  
4.5.3 New and Novel Vaccines Launches Targeting High-Risk Populations  
4.6 Restraints  
4.6.1 Vaccine Supply Shortage Issues  
4.6.2 High Start-up Costs and Special Technical Expertise Requirements for Vaccine Production  
4.6.3 Public Acceptance  
4.6.4 Austerity Measures Leading to a Drop in Healthcare Funding  
 
5 Travel Vaccines Market to 2019: Hepatitis A Vaccines  
5.1 Disease Overview  
5.2 Market Forecasts  
5.2.1 US  
5.2.2 Top Five European Countries  
5.2.3 Japan  
5.3 Cost of Vaccination  
5.3.1 US  
5.3.2 Top Five European Countries  
5.3.3 Japan  
5.4 Pipeline Analysis  
5.4.1 Phase III (Inactive)  
5.4.2 Preclinical and Discovery (Inactive)  
 
6 Travel Vaccines Market to 2019: Hepatitis B Vaccines  
6.1 Disease Overview  
6.2 Market Forecasts  
6.2.1 US  
6.2.2 Top Five European Countries  
6.2.3 Japan  
6.3 Cost of Vaccination  
6.3.1 US  
6.3.2 Top Five European Countries  
6.3.3 Japan  
6.4 Pipeline Analysis  
6.4.1 Registration and Phase III  
6.4.2 Phase II  
6.4.3 Phase I  
6.4.4 Preclinical and Discovery  
 
7 Travel Vaccines Market to 2019: Japanese Encephalitis Vaccines  
7.1 Disease Overview  
7.2 Market Forecasts  
7.2.1 US  
7.2.2 Top Five European Countries  
7.2.3 Japan  
7.3 Cost of Vaccination  
7.3.1 US  
7.3.2 Top Five European Countries  
7.3.3 Japan  
7.4 Pipeline Analysis  
7.4.1 Registration  
7.4.2 Preclinical and Discovery  
 
8 Travel Vaccines Market to 2019: Meningococcal Vaccines  
8.1 Disease Overview  
8.2 Market Forecasts  
8.2.1 US  
8.2.2 Top Five European Countries  
8.3 Cost of Vaccination  
8.3.1 US  
8.3.2 Top Five European Countries  
8.4 Pipeline Analysis  
8.4.1 Registration and Phase III  
8.4.2 Phase II  
8.4.3 Preclinical and Discovery  
 
9 Travel Vaccines Market to 2019: Rabies Vaccines  
9.1 Disease Overview  
9.2 Market Forecasts  
9.2.1 US  
9.2.2 Top Five European Countries  
9.2.3 Japan  
9.3 Cost of Vaccination  
9.3.1 US  
9.3.2 Top Five European Countries  
9.3.3 Japan  
9.4 Pipeline Analysis  
9.4.1 Phase II  
9.4.2 Phase I  
9.4.3 Preclinical  
 
10 Travel Vaccines Market to 2019: Typhoid Vaccines  
10.1 Disease Overview  
10.2 Market Forecasts  
10.2.1 US  
10.2.2 Top Five European Countries  
10.3 Cost of Vaccination  
10.3.1 US  
10.3.2 Top Five European Countries  
10.4 Pipeline Analysis  
10.4.1 Phase II  
10.4.2 Preclinical  
 
11 Travel Vaccines Market to 2019: Yellow Fever Vaccines  
11.1 Disease Overview  
11.2 Market Forecasts  
11.2.1 US  
11.2.2 Top Five European Countries  
11.2.3 Japan  
11.3 Cost of Vaccination  
11.3.1 US  
11.3.2 Top Five European Countries  
11.3.3 Japan  
11.4 Pipeline Analysis  
11.4.1 Phase III  
11.4.2 Phase I  
11.4.3 Preclinical and Discovery  
 
12 Travel Vaccines Market to 2019: Competitive Landscape  
12.1 Introduction  
12.2 Major Company Profiles  
12.2.1 GlaxoSmithKline  
12.2.2 Sanofi  
12.2.3 Pfizer  
12.2.4 Merck  
12.2.5 Novartis  
 
13 Travel Vaccines Market to 2019: Strategic Consolidations  
13.1 Deals by Year  
13.2 Deals by Type  
13.3 Deals by Value  
13.4 Deals by Geography  
13.5 Summary of Major M&A Deals  
13.5.1 Gilead Sciences Completes Acquisition of Pharmasset for $11.2 Billion  
13.5.2 Johnson & Johnson Acquires Crucell  
13.6 Summary of Major Licensing Deals  
13.6.1 Intercell Enters into Licensing Agreement with Novartis for IC51  
13.6.2 Gilead Sciences Enters into Licensing Agreement with GlobeImmune  
 
14 Vaccines in Asia-Pacific – India, China and Australia: Overview  
14.1 India  
14.1.1 Regulatory Framework  
14.1.2 Major Company Profiles  
14.2 Recent Developments  
14.2.1 Biological E. Launches Japanese Encephalitis Vaccine Jeev in India – September 2012  
14.2.2 Approvals by Central Drugs Standard Control Organization  
14.3 China  
14.3.1 Regulatory Framework  
14.3.2 Expanded Programme on Immunization  
14.3.3 Major Company Profiles  
14.4 Australia  
14.4.1 Regulatory Framework  
14.4.2 Designated Vaccines and Circumstances in which Vaccines may be Provided  
14.4.3 Immunization Schedule  
14.4.4 Major Company Profiles  
14.4.5 Recent Developments  
14.5 Vaccines in Emerging Markets: Strategic Consolidations  
14.5.1 Deals by Year  
14.5.2 Deals by Type  
14.5.3 Deals by Value  
14.6 Vaccines in Emerging Markets: Pipeline by Phase  
 
15 Travel Vaccines Market to 2019: Appendix  
15.1 Market Definitions  
15.2 Abbreviations  
15.3 Bibliography  
15.4 Research Methodology  
15.4.1 Coverage  
15.4.2 Secondary Research  
15.4.3 Primary Research  
15.4.4 Model for Estimation of Vaccine Market  
15.5 Geographical Landscape  
15.6 Pipeline Analysis  
15.7 Competitive Landscape  
15.7.1 Expert Panel Validation  
15.8 Contact Us  
15.9 Disclaimer 

List of Tables


Table 1: Travel Vaccines Market, Top Seven Markets, Vaccine-Preventable Diseases, 2012 Table 2: Travel Vaccines Market, Top Seven Markets, Traveler Population (million), 2007–2012  
Table 3: Travel Vaccines Market, Top Seven Markets, Traveler Population Forecast (million), 2012–2019  
Table 4: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue ($m), 2007–2012  
Table 5: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue Forecast ($m), 2012–2019  
Table 6: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue ($m), 2007–2012  
Table 7: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue Forecast ($m), 2012–2019  
Table 8: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue ($m), 2007–2012  
Table 9: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue Forecast ($m), 2012–2019  
Table 10: Travel Vaccines Market, US, Hepatitis A Vaccines, Cost ($), 2007–2012  
Table 11: Travel Vaccines Market, US, Hepatitis A Vaccines, Cost ($), 2012–2019  
Table 12: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Cost ($), 2007–2012  
Table 13: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Cost Forecast ($), 2012–2019  
Table 14: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Cost ($), 2007–2012  
Table 15: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Cost Forecast ($), 2012–2019  
Table 16: Travel Vaccines Market, Global, Hepatitis A Vaccines, Phase III (Inactive) Pipeline, 2012  
Table 17: Travel Vaccines Market, Global, Hepatitis A Vaccines, Preclinical and Discovery (Inactive) Pipeline, 2012  
Table 18: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue ($m), 2007–2012  
Table 19: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue Forecast ($m), 2012–2019  
Table 20: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue ($m), 2007–2012  
Table 21: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue Forecast ($m), 2012–2019  
Table 22: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue ($m), 2007–2012  
Table 23: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue Forecast ($m), 2012–2019  
Table 24: Travel Vaccines Market, US, Hepatitis B Vaccines, Cost ($), 2007–2012  
Table 25: Travel Vaccines Market, US, Hepatitis B Vaccines, Cost Forecast ($), 2012–2019  
Table 26: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Cost ($), 2007–2012  
Table 27: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Cost ($), 2012–2019  
Table 28: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Cost ($), 2007–2012  
Table 29: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Cost Forecast ($), 2012–2019  
Table 30: Travel Vaccines Market, Global, Hepatitis B Vaccines, Registration and Phase III Pipeline, 2012  
Table 31: Travel Vaccines Market, Global, Hepatitis B Vaccines, Phase II Pipeline, 2012  
Table 32: Travel Vaccines Market, Global, Hepatitis B Vaccines, Phase I Pipeline, 2012  
Table 33: Travel Vaccines Market, Global, Hepatitis B Vaccines, Preclinical and Discovery Pipeline, 2012  
Table 34: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue ($m), 2007–2012  
Table 35: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2012–2019  
Table 36: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Revenue ($m), 2007–2012  
Table 37: Travel Vaccines Market to 2019, Japanese Encephalitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2012–2019  
Table 38: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue ($m), 2007–2012  
Table 39: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2012–2019  
Table 40: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Cost ($), 2007–2012  
Table 41: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012–2019  
Table 42: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Cost ($), 2007–2012  
Table 43: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012–2019  
Table 44: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Cost ($), 2007–2012  
Table 45: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012–2019  
Table 46: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Registration, 2012  
Table 47: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Preclinical and Discovery, 2012  
Table 48: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue ($m), 2007–2012  
Table 49: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue Forecast ($m), 2012–2019  
Table 50: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue ($m), 2007–2012  
Table 51: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue Forecast ($m), 2012–2019  
Table 52: Travel Vaccines Market, US, Meningococcal Vaccines, Cost ($), 2007–2012  
Table 53: Travel Vaccines Market, US, Meningococcal Vaccines, Cost Forecast ($), 2012–2019  
Table 54: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Cost ($), 2007–2012  
Table 55: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Cost Forecast ($), 2012–2019  
Table 56: Travel Vaccines Market, Global, Meningococcal Vaccines, Registration and Phase III Pipeline, 2012  
Table 57: Travel Vaccines Market, Global, Meningococcal Vaccines, Phase II Pipeline, 2012  
Table 58: Travel Vaccines Market, Global, Meningococcal Vaccines, Preclinical Pipeline, 2012  
Table 59: Travel Vaccines Market, US, Rabies Vaccines, Revenue ($m), 2007–2012  
Table 60: Travel Vaccines Market, US, Rabies Vaccines, Revenue Forecast ($m), 2012–2019  
Table 61: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue ($m), 2007–2012  
Table 62: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue Forecast ($m), 2012–2019  
Table 63: Travel Vaccines Market, Japan, Rabies Vaccines, Revenue ($m), 2007–2012  
Table 64: Travel Vaccines Market, Japan, Rabies Vaccines, Revenue Forecast ($m), 2012–2019  
Table 65: Travel Vaccines Market, US, Rabies Vaccines, Cost ($), 2007–2012  
Table 66: Travel Vaccines Market, US, Rabies Vaccines, Cost Forecast ($), 2012–2019  
Table 67: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Cost ($), 2007–2012  
Table 68: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Cost Forecast ($), 2012–2019  
Table 69: Travel Vaccines Market, Japan, Rabies Vaccines, Cost ($), 2007–2012  
Table 70: Travel Vaccines Market, Japan. Rabies Vaccines, Cost Forecast ($), 2012–2019  
Table 71: Travel Vaccines Market, Global, Rabies Vaccines, Phase II Pipeline, 2012  
Table 72: Travel Vaccines Market, Global, Rabies Vaccines, Phase I Pipeline, 2012  
Table 73: Travel Vaccines Market, Global, Rabies Vaccines, Preclinical Pipeline, 2012  
Table 74: Travel Vaccines Market, US, Typhoid Vaccines, Revenue ($m), 2007–2012  
Table 75: Travel Vaccines Market, US, Typhoid Vaccines, Revenue Forecast ($m), 2012–2019  
Table 76: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue ($m), 2007–2012  
Table 77: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue Forecast ($m), 2012–2019  
Table 78: Travel Vaccines Market, US, Typhoid Vaccines, Cost ($), 2007–2012  
Table 79: Travel Vaccines Market, US, Typhoid Vaccines, Cost Forecast ($), 2012–2019  
Table 80: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Cost ($), 2007–2012  
Table 81: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Cost Forecast ($), 2012–2019  
Table 82: Travel Vaccines Market, Global, Typhoid Vaccines, Phase II Pipeline, 2012  
Table 83: Travel Vaccines Market, Global, Typhoid Vaccines, Preclinical Pipeline, 2012  
Table 84: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue ($m), 2007–2012  
Table 85: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue Forecast ($m), 2012–2019  
Table 86: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue ($m), 2007–2012  
Table 87: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue Forecast ($m), 2012–2019  
Table 88: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue ($m), 2007–2012  
Table 89: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue Forecast ($m), 2012–2019  
Table 90: Travel Vaccines Market, US, Yellow Fever Vaccines, Cost ($), 2007–2012  
Table 91: Travel Vaccines Market, US, Yellow Fever Vaccines, Cost Forecast ($), 2012–2019  
Table 92: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Cost ($), 2007–2012  
Table 93: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Cost Forecast ($), 2012–2019  
Table 94: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Cost ($), 2007–2012  
Table 95: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Cost Forecast ($), 2012–2019  
Table 96: Travel Vaccines Market, Global, Yellow Fever Vaccines, Phase III, 2012  
Table 97: Travel Vaccines Market, Global, Yellow Fever Vaccines, Phase I, 2012  
Table 98: Travel Vaccines Market, Global, Yellow Fever Vaccines, Preclinical and Discovery, 2012  
Table 99: Travel Vaccines Market, India, Immunization Schedule, 2012  
Table 100: Travel Vaccines Market, India, Major Vaccine Brands by Indication, 2012  
Table 101: Travel Vaccines Market, China, Policies, 2012  
Table 102: Travel Vaccines Market, Australia, Designated Bacterial Vaccines and Circumstances in which Vaccines may be Provided, 2011  
Table 103: Travel Vaccines Market, Australia, Designated Viral Vaccines and Circumstances in which Vaccines may be Provided, 2011  
Table 104: Travel Vaccines Market, Australia, Designated Combined Bacterial and Viral Vaccines and Circumstances in which Vaccines may be Provided, 2011  
Table 105: Travel Vaccines Market, Australia, Immunization Schedule, 2012  
Table 106: Travel Vaccines Market, Emerging Markets, Pipeline by Phase, 2012 

List of Figures


Figure 1: Travel Vaccines Market, Global, Vaccine Types, 2012  
Figure 2: Travel Vaccines Market, Global, Vaccine Manufacturing Process, 2012  
Figure 3: Travel Vaccines Market, Top Seven Markets, Revenue Forecast ($m), 2007–2019 
Figure 4: Travel Vaccines Market, Top Seven Markets, Market Share by Vaccine Type (%), 2012  
Figure 5: Travel Vaccines Market, Top Seven Markets, Market Share by Geography (%), 2012  
Figure 6: Travel Vaccines Market, Top Seven Markets, Traveling Population (million), 2007–2019  
Figure 7: Travel Vaccines Market, Global, Geographical Distribution of Hepatitis A, 2012  
Figure 8: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 9: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 10: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 11: Travel Vaccines Market, Global, Hepatitis A Vaccines, Pipeline by Phase (%), 2012  
Figure 12: Travel Vaccines Market, Global, Geographical Distribution of Hepatitis B, 2012  
Figure 13: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 14: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 15: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 16: Travel Vaccines Market, Global, Hepatitis B Vaccines, Pipeline by Phase (%), 2012  
Figure 17: Travel Vaccines Market, Global, Geographical Distribution of Japanese Encephalitis, 2012  
Figure 18: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 19: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 20: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 21: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Pipeline by Phase (%), 2012  
Figure 22: Travel Vaccines Market, Global, Geographical Distribution of Meningococcal Meningitis, 2012  
Figure 23: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 24: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 25: Travel Vaccines Market, Global, Meningococcal Vaccines, Pipeline by Phase (%), 2012  
Figure 26: Travel Vaccines Market, Global, Geographical Distribution of Rabies, 2012  
Figure 27: Travel Vaccines Market, US, Rabies Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 28: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 29: Travel Vaccines Market, Japan. Rabies Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 30: Travel Vaccines Market, Global, Rabies Vaccines, Pipeline by Phase (%), 2012  
Figure 31: Travel Vaccines Market, Global, Geographical Distribution of Typhoid, 2012  
Figure 32: Travel Vaccines Market, US, Typhoid Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 33: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 34: Travel Vaccines Market, Global, Typhoid Vaccines, Pipeline by Phase (%), 2012  
Figure 35: Travel Vaccines Market, Global, Geographical Distribution of Yellow Fever, 2012  
Figure 36: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 37: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 38: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue Forecast ($m), 2007–2019  
Figure 39: Travel Vaccines Market, Global, Yellow Fever Vaccines, Pipeline by Phase (%), 2012  
Figure 40: GlaxoSmithKline, Travel Vaccines Market, SWOT Analysis, 2012  
Figure 41: Sanofi, Travel Vaccines Market, SWOT Analysis, 2012  
Figure 42: Pfizer, Travel Vaccines Market, SWOT Analysis, 2012  
Figure 43: Merck, Travel Vaccines Market, SWOT Analysis, 2012  
Figure 44: Novartis, Travel Vaccines Market, SWOT Analysis, 2012  
Figure 45: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Year, 2009–2013  
Figure 46: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Type, 2008–2013  
Figure 47: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Value, 2008–2013  
Figure 48: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Geography, 2008–2013  
Figure 49: Vaccines in Emerging Markets, India, National Rural Health Mission, 2011  
Figure 50: Vaccines in Emerging Markets, Deals by Year, 2009–2013  
Figure 51: Travel Vaccines Market, Emerging Markets, Deals by Type (%), 2009–2013  
Figure 52: Travel Vaccines Market, Emerging Markets, Deals by Value ($m), 2009–2013  
Figure 53: Travel Vaccines Market, Emerging Markets, Pipeline by Phase (%), 2012  
Figure 54: GBI Research Market Forecasting Model 

Upcoming Reports:

Spinal Non-Fusion Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Inception of non-fusion technologies into spinal surgery has improved outcomes by providing patients to retain at least some movement and flexibility in the spine. The global market for spinal nonfusion technologies comprises of disc arthroplasty, nuclear arthroplasty and nuclear disc prostheses. These artificial discs are composed of metal, soft plastic like materials or a combination of both such as medical grade plastic and medical grade cobalt chromium or titanium alloy enabling flexibility to spine. Disc arthroplasty is a surgical procedure in which degenerated spinal discs are...
Flexible Electronics Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Flexible electronics industry combines technical sectors such as polymers, advance materials, flexible displays and more. Each of these sectors are creating new applications in flexible electronics devices, which are applied in medical, advance energy, military, industrial and consumer markets. The flexible electronics industry is driven by the global need to create products which are small, light weight and consume less power. As such devices have flexible structure, low manufacturing cost and are more resistant to shock; they can be integrated with various industrial...
Diabetic Food Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Large diabetic population is a major driver for the global diabetic food market. In 2013, around 347 million people were diabetic worldwide. Other major factors contributing to market growth are increasing health awareness and rising obesity levels. The people who are not diabetic also consume diabetic products as precautionary measures of getting diabetic. Different type of ‘reduced sugar and carbohydrate’ food products are available under diabetic foods segment. Packaged food that are labelled as ‘low in sugar’, ‘suitable for diabetics’ and containing...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Early Treatment to Cure HIV virus Might not be Effective
Jul 23, 2014  
According to a research study, the virus of AIDS, HIV has the capacity of creating invulnerable strongholds in the host’s body rapidly. This has dashed hopes of early treatment for the condition, which might have been helpful to cure the virus. In one case, a baby was thought to be cured with the new treatment after its birth, however, the virus emerged couple of years later. A...
Pharmaceutical Companies in Europe to Share Deprioritized Compounds for Medical Research
Jul 23, 2014  
Seven leading drugmakers in the UK have decided to share their unused experimental medicines with British researchers involved in academic research. This move is seen as an effort to deepen relations between the pharmaceutical industry and the community of scientists in the country. The new partnership between the seven pharma companies and the Medical Research Council (MRC) was...